<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914680</url>
  </required_header>
  <id_info>
    <org_study_id>BEMAST1</org_study_id>
    <nct_id>NCT00914680</nct_id>
  </id_info>
  <brief_title>Berlin Magnetic Seizure Therapy Depression Trial 01</brief_title>
  <official_title>Investigation of Efficacy and Tolerability of Magnetic Seizure Therapy in the Treatment of Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This treatment pilot study will investigate clinical efficacy and adverse effects of
      magnetic seizure therapy (MST) in patients currently experiencing a unipolar or bipolar
      depressive episode. The investigators will perform add-on tests to assess clinical and
      cognitive response to treatment. It is hypothesized that MST will have an antidepressant
      efficacy with a beneficial neurocognitive adverse effect profile.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Improvement (HAMD)</measure>
    <time_frame>before, after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive performance</measure>
    <time_frame>before/after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Unipolar Depression</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>MST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic seizure therapy</intervention_name>
    <description>antidepressant treatment with MST</description>
    <arm_group_label>MST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is diagnosed with a severe major depressive episode

          -  Patient is in a chronic current MDE and/or has had a history of recurrent MDEs

          -  Patient has not had an acceptable clinical response due to failure with at least 2
             antidepressant treatments during the current episode

          -  Patient has a score &gt; 20 on the HAMD24

          -  Patient is stable on current psychotropic medication for at least 4 weeks

          -  Patient is &gt; 25 and &lt; 80 years

        Exclusion Criteria:

          -  Atypical Depression or psychotic depression (according to DSM IV)

          -  Other relevant psychiatric axis I or axis II diseases

          -  Relevant neurological diseases

          -  Relevant cardiac or pulmonary diseases with enhances anesthesiological risk (ASA
             Score &gt; 3)

          -  Patient is currently enrolled in another investigational study not associated with
             the current study

          -  Patient has a history of, or evidence of, significant brain malformation or
             significant head injury
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lara Rzesnitzek</last_name>
    <phone>+49 30 8445 8780</phone>
    <email>lara.rzesnitzek@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bettina Wächter</last_name>
    <phone>+49 30 8445 8658</phone>
    <email>bettina.waechter@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry, CC15, CBF, Eschenallee 3</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Rzesnitzek</last_name>
      <email>lara.rzesnitzek@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Bettina Wächter</last_name>
      <email>bettina.waechter@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Malek Bajbouj</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lara Rzesnitzek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bettina Wächter</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.charite-psychiatrie.de</url>
  </link>
  <verification_date>June 2009</verification_date>
  <lastchanged_date>July 20, 2011</lastchanged_date>
  <firstreceived_date>June 3, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Malek Bajbouj</name_title>
    <organization>Charité</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
